The primary hypothesis of our study was to determine if high dose RES, administered to obese men with insulin resistance and the MetS, would improve insulin sensitivity, glucose tolerance, and other features of the MetS and thus possibly contribute to established therapies of the disease. Here, INS is linked to metabolic syndrome.